Transition Therapeutics diabetes trial underway
E1-INT is a short course combination therapy aimed at stimulating the regeneration of the body’s insulin-producing cells, called islet cells. “Expansion into type 2 diabetes significantly broadens the
Japan-based Ono Pharmaceutical has signed an agreement with US biotechnology company Aitia to collaborate on drug discovery in neurological diseases.